SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
Recruiting
- Conditions
- Crohn DiseaseUlcerative ColitisRheumatoid ArthritisAnkylosing SpondylitisPsoriatic Arthritis
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Fresenius Kabi, France
- Target Recruit Count
- 600
- Registration Number
- NCT05598684
- Locations
- 🇫🇷
Ch Amiens Nord, Amiens, France
🇫🇷Nouvelle Clinique BONNEFON, Alès, France
🇫🇷Chu Amiens Picardie Site Sud, Amiens, France
© Copyright 2025. All Rights Reserved by MedPath